Clinical Trial Update: A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs [Phase 3]

View source ↗

Summary

Phase 3 study evaluating tocilizumab in combination with DMARDs for moderate-to-severe rheumatoid arthritis with inadequate response to DMARDs; the trial was co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Actemra (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2016-11-09